Floatz logo

MDG1015

Myxoid Liposarcoma

Medigene AGPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Myxoid Liposarcoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Medigene AG
Phase 2B
Pembrolizumab
Valo Therapeutics Oy
Phase 2B
Interferon Gamma-1B
National Cancer Institute (NCI)
Phase 2B
Hycamtin
Salarius Pharmaceuticals, LLC
Phase 1CC
Pepticrad-1
Valo Therapeutics Oy
Phase 1CC
Seclidemstat
Salarius Pharmaceuticals, LLC
Phase 1CC

Same molecule, other indications

MDG1015 is also rated in:

soft tissue sarcomaDormant
CC
Indicative ·
43 / 100
View asset →
gastroesophageal junction adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
synovial sarcomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →